Downloads: 117

Files in This Item:
File Description SizeFormat 
s13256-017-1213-7.pdf1 MBAdobe PDFView/Open
Title: Chemotherapy for primary mediastinal yolk sac tumor in a patient undergoing chronic hemodialysis: a case report
Authors: Hirakawa, Haruki
Nakashima, Chiho
Nakamura, Tomomi
Masuda, Masanori
Funakoshi, Taro
Nakagawa, Shunsaku  kyouindb  KAKEN_id
Horimatsu, Takahiro  kyouindb  KAKEN_id
Matsubara, Kazuo  kyouindb  KAKEN_id
Muto, Manabu  kyouindb  KAKEN_id
Kimura, Shinya
Sueoka-Aragane, Naoko
Author's alias: 堀松, 高博
Keywords: Cisplatin
Hemodialysis
Mediastinal yolk sac tumor
Pharmacokinetics
Renal insufficiency
Issue Date: 16-Feb-2017
Publisher: BioMed Central Ltd.
Journal title: Journal of Medical Case Reports
Volume: 11
Thesis number: 43
Abstract: Background: The safety and efficacy of chemotherapy for patients undergoing concomitant hemodialysis have not been fully established and optimal doses of anti-cancer drugs and best timing of hemodialysis remains unclear. Although chemosensitive cancers, such as germ cell tumors, treated with chemotherapy should have sufficient dose intensity maintained to achieve the desired effect, many patients with cancer undergoing hemodialysis might be under-treated because the pharmacokinetics of anti-cancer drugs in such patients remains unknown. Case presentation: We describe a 31-year-old Japanese man with a mediastinal yolk sac tumor treated with surgery followed by five cycles of chemotherapy containing cisplatin and etoposide while concomitantly undergoing hemodialysis. The doses of these agents used in the first cycle were 50% of the standard dose of cisplatin (10 mg/m2) and 60% of the standard dose of etoposide (60 mg/m2) on days 1 through to 5; the doses were subsequently escalated to 75% with both agents. Hemodialysis was started 1 hour after infusions of these agents. Severe hematological toxicities were observed despite successful treatment. During treatment with concurrent hemodialysis, pharmacokinetic analysis of cisplatin was performed and its relationship with adverse effects was assessed. Compared with patients with normal renal function, the maximum drug concentration was higher, and concentration increased in the interval between hemodialysis and the subsequent cisplatin infusion, resulting in a higher area under the curve despite a reduction in the dose to 75% of the standard regimen. Conclusions: Because of the altered pharmacokinetics pharmacodynamics status of patients with renal dysfunction undergoing hemodialysis, pharmacokinetics pharmacodynamics analysis is deemed to be helpful for effective and safe management of chemotherapy in patients undergoing hemodialysis.
Rights: © The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
URI: http://hdl.handle.net/2433/218419
DOI(Published Version): 10.1186/s13256-017-1213-7
PubMed ID: 28202048
Appears in Collections:Journal Articles

Show full item record

Export to RefWorks


Export Format: 


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.